Anida Pharma, Inc. is a biopharmaceutical company developing new therapies to treat amyotrophic lateral sclerosis (ALS; Lou Gehrig disease), Parkinson’s disease (PD), other central nervous system disorders, and hearing loss. Anida is developing first-in-class therapeutics and will bring to the clinic compounds that activate the body's own mechanisms to regulate inflammation, cell survival and promote tissue repair. By activating the body’s own pathways they offer the potential of being highly efficacious and also exceptionally safe.

There is a significant unmet medical need to develop therapies that will slow progression of disease in both ALS and PD. Current therapies in ALS at best have a modest effect in slowing progression for some patients, and for patients with Parkinson's disease no disease modifying therapy is available. The same is true for hearing loss, whether drug or noise induced. No therapy exists to prevent or restore loss of hearing that will be permanent, a particular concern for pediatric patients in various cancer and infectious disease regimens.